POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

First-line treatment options for castration-resistant prostate cancer (CRPC) include both docetaxel (DOC; available in the Netherlands since 2004) or abiraterone acetate plus prednisone (ABI; available in the Netherlands for chemotherapy-naïve since 2013). Overall survival (OS) of DOC or ABI do not significantly differ in indirect comparisons, while there is a difference in drug costs. Consequently, treatment costs might be considered when selecting a first-line treatment. This study aimed to evaluate costs and survival of the whole treatment pathway of real-world CRPC-patients that received either first-line DOC or ABI using propensity score matching (PSM).